Chief Science Officer · Insight Molecular Diagnostics Inc. (IMDX)

Ekkehard Schütz

A named executive officer of Insight Molecular Diagnostics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$633,568

Salary $370,356Stock awards $0Bonus $166,800

FY2023: $575,167

3rd of 4 named executive officers at Insight Molecular Diagnostics by FY2024 total.

4 named officers on file for Insight Molecular Diagnostics, FY2024

Ekkehard Schütz’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Insight Molecular Diagnostics’s whole pay program stands against its peers

  • Insight Molecular Diagnostics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 14, 2025 (DEF 14A).

Free

Get Ekkehard Schütz’s full pay file as a PDF — free

More than this page: up to 10 years of Ekkehard’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ekkehard Schütz compensation by year

Insight Molecular Diagnostics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Insight Molecular Diagnostics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$242,028$370,356
Bonus$132,700$166,800
Stock awards$0$0
Option awards$165,892$81,554
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$34,547$14,858
Total$575,167$633,568

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Insight Molecular Diagnostics Inc. DEF 14A filed May 14, 2025, accession 0001641172-25-010366, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Insight Molecular Diagnostics Inc. filed document, accession 0001641172-25-010366. Every figure is read from that document and cited to the page and table it appears in. Filed May 14, 2025.

$575K
$634K
FY23
FY24
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option2,349—$7.80
Option35,000—$2.76
Option1,094—$23.00
Option1,043—$109.20
Option8,582—$9.26
Option20,000—$3.34

Per the Outstanding Equity Awards at Fiscal Year-End table in Insight Molecular Diagnostics Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insight Molecular Diagnostics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Joshua RiggsPresident and Chief Executive Officer$786,077
Andrea JamesChief Financial Officer$758,863
Ekkehard Schütz · this pageChief Science Officer$633,568
James LiuSenior Director, Controller and Principal Accounting Officer$303,928

The full Insight Molecular Diagnostics compensation record

free company brief

This page is one person within Insight Molecular Diagnostics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Insight Molecular Diagnostics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ekkehard Schütz's compensation dossier · One-time report. No refunds.